When a DPP4i is needed
Proven efficacy for your T2D patients1.
Adjusted mean HbA1c change from baseline at 24 weeks in patients with high baseline values*
*Pooled analysis of data from 2,258 subjects in three 24-week phase III, randomised, placebo-controlled, parallel-group studies, who received oral linagliptin (5 mg/day) or placebo as monotherapy, added-on to metformin, or added-on to metformin plus sulphonylurea was performed. Adjusted mean HbA1c change from baseline with linagliptin was -1.2% (vs -0.4% with placebo, p<0.0001).